Comparing new drug combo with standard chemo for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new combination of drugs (HS-20093 plus adebrelimab) against a standard chemotherapy (docetaxel) for people with advanced or metastatic non-squamous non-small cell lung cancer who have already had treatment. The goal is to see if the new combination is more effective and safer than the standard chemo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of advanced or metastatic non-squamous non-small cell lung cancer that has been treated before, but without specific genetic changes that have targeted therapies.
- You must have at least one tumor that can be measured on scans.
- You must be able to take care of yourself (fully active or up and about, but not bedridden).
- You must have adequate organ function, meaning your heart, liver, kidneys, and blood counts are within a safe range.
- You must not have active infections like hepatitis B, hepatitis C, HIV, tuberculosis, or syphilis.
- You must not have prior treatment with docetaxel, a drug targeting B7-H3, or a topoisomerase I inhibitor (a type of chemotherapy).
- You must not have untreated or uncontrolled brain metastases, cancer spread to the spinal fluid or brainstem, or spinal cord compression.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (HS-20093) alone versus combined with another drug (adebrelimab) for people with advanced or metastatic non-squamous non-small cell lung cancer who have already been treated. The goal is to see if the combination works better at shrinking tumors or slowing cancer growth.
This trial tests a new drug (RC148) plus chemotherapy against another drug (Tislelizumab) plus chemotherapy for people with a type of lung cancer called squamous non-small cell lung cancer that has spread or can't be removed. It's for those who haven't had treatment for advanced disease yet.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial compares a new drug called SYS6010 to a standard chemotherapy drug (docetaxel) for people with advanced non-small cell lung cancer that has not responded to previous treatments. The goal is to see if the new drug works better or has fewer side effects.
This trial tests a new drug combined with other treatments for people with lung cancer that can be removed by surgery. It aims to see if the treatment shrinks tumors before surgery and improves outcomes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.